Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma), drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
No randomised trial has ever been run in this entity. The intensified regimens used for it were adopted from retrospective comparisons, and whether they are better than standard immunochemotherapy for an individual patient is not known.
The test used to make the diagnosis identifies a narrower group than the biology does: the double-hit gene expression signature marks about twice as many patients as the rearrangements do, and those extra patients have the same outcome and are treated as ordinary diffuse large B-cell lymphoma.
The two 2022 classifications handle MYC with BCL6 differently, so the same biopsy can yield two different diagnoses and two different trial eligibilities.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
Every aggressive B-cell lymphoma biopsy is tested by fluorescence in situ hybridisation for MYC, and if MYC is rearranged, for BCL2 and BCL6. A lymphoma cannot be identified as double-hit by appearance, by immunohistochemistry for MYC and BCL2 protein, or by the cell-of-origin assay; dual protein expression is a separate and much commoner finding with its own, lesser, prognostic weight. Follicular lymphoma is excluded from the entity by both classifications even when it carries both rearrangements.
Both removed cases with MYC and BCL6 rearrangements from the double-hit entity. WHO-HAEM5 reassigns them by appearance; the International Consensus Classification made them a provisional entity of their own.
An analysis of 157 germinal-centre diffuse large B-cell lymphomas defined a 104-gene double-hit signature present in 27 per cent of them, only half of which carried the rearrangements; those with the signature had a five-year time to progression of 57 per cent against 81 per cent.
The revised fourth edition of the WHO classification created high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as a category of its own, which made testing for the rearrangements routine.